Cutaneous Malignant Melanomas: Epidemiological, Clinical and Therapeutic Aspects. Experience of the Plastic Surgery Department in Mohammed Vi Hospital of Marrakech- Morocco.

Abstract

CTLA4 monoclonal antibodies and targeted therapy with inhibitors of BRAF or MEK for melanoma with BRAF mutated, recent studies have shown that the combination of inhibitors of BRAF and inhibitors of MEK may improve the progression-free survival and eventually increase overall survival, the choice of therapy should be individualized in each case depending on various factors such as BRAF mutation status, age, co-morbidities and topography of metastases ,while chemotherapy and radiation therapy can be used to relieve the symptoms without significant impact on patient survival. Preventing melanoma is a real public health problem requires education of the general population on the need for sunscreen and awareness of melanoma and encouraging early diagnosis with the training of health professionals.